Tau PET scan study for Alzheimer’s disease
Part of Brain & nervous system, Mental health clinical trials.
This study uses a PET brain scan with a small injected tracer to look for “tau” protein changes linked to Alzheimer’s disease. It may help researchers better understand how tau appears in people who are cognitively normal or have mild dementia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can follow study instructions.
- You have no major thinking problems or have mild dementia, based on the study doctor’s assessment.
- You can safely do the scan steps, which may include an MRI or CT, a PET scan, and an injection of the tracer.
- You are not pregnant or breastfeeding (and you may need a pregnancy test if you can become pregnant).
- You can lie still during scans and you do not have severe fear of enclosed spaces (claustrophobia).
- You are not taking medicines that significantly increase heart rhythm risk (QT-prolonging drugs) and you don’t have a high-risk history for that issue. (If you choose the optional spinal tap, you can’t be on blood thinners.)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special brain scan to measure “tau” buildup in people with an inherited form of Alzheimer’s. It may help researchers better understand disease changes and evaluate whether the scan can track them over time.
This study tests a PET scan “tracer” medicine called [18F]MK-6240 to see how tau protein changes show up in the brain. It may help researchers measure disease-related brain changes in people with normal thinking or mild dementia.
This study uses brain scans to see how anti-amyloid treatments affect tau protein buildup in people with early Alzheimer's. If you have mild cognitive impairment or mild Alzheimer's, you may be eligible to help understand how these treatments work.
This trial tests an added brain imaging scan that looks for “tau” protein in people already enrolled in the UAB Alzheimer research studies. Results may help researchers better understand Alzheimer’s disease and improve future diagnosis.
This Phase 3 study uses a PET/CT scan to measure whether a brain protein called tau (and related disease patterns) builds up in different dementia conditions. The goal is to better match which disorders have which brain changes and how they progress.
This study compares two types of brain PET scans (tau and amyloid) to see which one better helps diagnose memory problems. You may be eligible if you have mild cognitive impairment or mild dementia and your doctor has already ordered an amyloid PET scan.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.